Updated:
OrbiMed Advisors
OrbiMed is a global investment firm that invests in companies engaged in the discovery and development of biopharmaceutical products, medical technologies,...
OrbiMed Advisors
OrbiMed is a global investment firm that invests in companies engaged in the discovery and development of biopharmaceutical products, medical technologies, medical devices, diagnostics, drug discovery tools, and healthcare information technology and services companies. It invests across the global healthcare industry, from seed-stage venture capital to large publicly-traded companies. Investments are made in one of three strategies: public equity, private equity, and private credit/royalty. The firm manages approximately $20 billion across public and private company investments worldwide.
General information
Firm type
Generalist
Year founded
1989
AUM
~$20B (per the firm)
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Additional offices
San Francisco, CA · Shanghai, China · Herzliya, Israel · Hong Kong · London, UK
Sector focus
Frequently asked questions
What geographies does OrbiMed cover?
OrbiMed invests globally with offices in New York, San Francisco, Shanghai, Herzliya, Hong Kong, and London. Its portfolio includes companies headquartered in North America, Asia, and Europe, and it has committed over $2 billion specifically to developing-country healthcare infrastructure.
What sets OrbiMed's model apart from a pure venture capital firm in healthcare?
OrbiMed combines venture capital with public equity hedge funds and a structured credit/royalty business — all under one healthcare mandate. This allows the firm to provide equity early, non-dilutive debt later, and maintain public-market exposure post-IPO, which is uncommon among dedicated life-sciences VCs.
How large is OrbiMed's team, and what expertise does it bring?
The firm employs over 150 professionals, including scientists, medical experts, and investment staff. This multidisciplinary team supports due diligence across biopharma, medical devices, diagnostics, healthcare IT, and services globally.
How active is OrbiMed in company creation versus backing existing start-ups?
OrbiMed has backed over 110 life sciences start-ups and its venture portfolio companies have brought over 80 new therapies to patients. The firm engages in both company creation and investment in established private companies, often taking an active role in building management teams and strategic direction.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: